


Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

August 2026

The logo for PHARMAC (Te Pātaka Whaioranga) is centered within a white circle. The background of the entire page is a solid grey color. Below the circle, there are stylized, concentric, wavy lines in white and grey, resembling a stylized sun or a series of overlapping waves. The text "PHARMAC" is in a large, bold, sans-serif font, and "TE PĀTAKA WHAIORANGA" is in a smaller, bold, sans-serif font below it.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 August 2026..... 3

Section H changes to Part II 4

Index 7

Summary of decisions

EFFECTIVE 1 AUGUST 2026

- Amikacin (Medsurge) inj 250 mg per ml, 2 ml vial – new listing
- Amino acid formula (Alfamino) powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can – Pharmacode 2632187 delisted 1 August 2026
- Aztreonam (Aztreonam (Fresenius Kabi)) inj 1 g vial – new listing
- Diatrizoate meglumine with sodium amidotrizoate inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle (Urografin) oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle (Gastrografin) – delisted 1 August 2026
- Erythromycin (as lactobionate) inj 500 mg vial (Eritrotex) and inj 1 g vial (Amdipharm) – new listing
- Granisetron (Granisetron-AFT) inj 1 mg per ml, 3 ml ampoule – new listing and addition of PSS
- Granisetron (Deva) inj 1 mg per ml, 3 ml ampoule – to be delisted 1 January 2027
- Ifosfamide with mesna (Ifomid – M) inj 2 g vial with mesna 3 x 100 mg per ml, 4 ml ampoule – new listing
- Ketamine (Ketalar) inj 100 mg per ml, 2 ml vial – addition of PSS
- Lenalidomide (Viatris) (Lenalidomide Viatris) cap 25 mg – Pharmacode 2673568 to be delisted 1 January 2027
- Low electrolyte oral feed 2 kcal/ml (Renilon 7.5 (apricot and caramel)) liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton – new Pharmacode listing
- Oestradiol valerate (Progynova) tab 1 mg and 2 mg – new Pharmacode listings
- Parecoxib (Parecoxib Juno) inj 40 mg vial – delisted 1 August 2026
- Promethazine hydrochloride (DBL Promethazine Hydrochloride) inj 25 mg per ml, 2 ml ampoule – amended brand name
- Propranolol (Propranolol LA Lupin) cap long-acting 160 mg – new listing
- Rituximab (Riximyo) inj 10 mg per ml, 10 ml vial and inj 10 mg per ml, 50 ml vial – amended restriction criteria
- Tetracycline (Tetracycline AA) cap 250 mg – new listing

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2026

CARDIOVASCULAR SYSTEM

48	PROPRANOLOL (new listing) Cap long-acting 160 mg	35.15	100	Propranolol LA Lupin
----	---	-------	-----	----------------------

HORMONE PREPARATIONS

81	OESTRADIOL VALERATE (new listing) Tab 1 mg – 5% DV Dec-25 to 2028	12.36	84	Progynova
	Tab 2 mg – 5% DV Dec-25 to 2028	12.36	84	Progynova
Note – these are new Pharmacode listings, 2734761 (1 mg) and 2734788 (2 mg).				

INFECTIONS

89	AMIKACIN (new listing) → Inj 250 mg per ml, 2 ml vial	169.97	5	Medsurge
91	ERYTHROMYCIN (AS LACTOBIONATE) (new listing) Inj 500 mg vial	59.95	1	Eritrox
	Inj 1 g vial	125.95	1	Amdipharm
95	TETRACYCLINE (new listing) Cap 250 mg	35.90	100	Tetracycline AA
96	AZTREONAM (new listing) → Inj 1 g vial	364.92	10	Aztreonam (Fresenius Kabi)

MUSCULOSKELETAL SYSTEM

120	PARECOXIB (delisted) Inj 40 mg vial	46.00	10	Parecoxib Juno
Note – Parecoxib Juno inj 40 mg vial delisted 1 August 2026.				

NERVOUS SYSTEM

123	KETAMINE (addition of PSS) Inj 100 mg per ml, 2 ml vial – 5% DV Jan-27 to 2029	91.98	5	Ketalar
134	GRANISETRON (brand change and addition of PSS) Inj 1 mg per ml, 3 ml ampoule – 5% DV Jan-27 to 2029	1.71	1	Granisetron-AFT
Note – Deva inj 1 mg per ml, 3 ml ampoule to be delisted from 1 January 2027.				

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2026 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

151	IFOSFAMIDE WITH MESNA Inj 2 g vial with mesna 3 x 100 mg per ml, 4 ml ampoule	62.00	1	Ifomid - M
155	LENALIDOMIDE (VIATRIS) (delisting) → Cap 25 mg – 5% DV Feb-25 to 31 Jan 2028	65.09	21	Lenalidomide Viatris
Note – Lenalidomide Viatris cap 25 mg to be delisted from 1 January 2027. This delist applies to Pharmacode 2673568.				
221	RITUXIMAB (RIXIMOY) (amended restriction criteria – affected criteria shown only) → Inj 10 mg per ml, 10 ml vial	275.33	2	Riximyo
	→ Inj 10 mg per ml, 50 ml vial	688.20	1	Riximyo
Restricted Initiation – thrombotic thrombocytopenic purpura (TTP) Haematologist All of the following: 1 The total rituximab dose per cycle would not exceed the equivalent of 375 mg/m ² of body surface area per week for a total of 4 weeks; and 2 Each treatment cycle at least 6 months apart; and 3 Either Any of the following: 3.1 Patient has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or 3.2 Patient has acute idiopathic TTP* with neurological or cardiovascular pathology; or 3.3 Patient has a history of immune-mediated thrombotic thrombocytopenic purpura, currently in clinical remission but has demonstrated a decline in ADAMTS13 levels or equivalent, consistent with high risk of relapse.				
Note: Indications marked with * are unapproved indications.				

RESPIRATORY SYSTEM AND ALLERGIES

263	PROMETHAZINE HYDROCHLORIDE (amended brand name) Inj 25 mg per ml, 2 ml ampoule	21.09	5	Hespira DBL Promethazine Hydrochloride
-----	---	-------	---	---

VARIOUS

283	DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE (delisted) Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle	30.00	100 ml	Gastrografin
	Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle	120.00	1	Urografin
Note – Gastrografin oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle (Pharmacodes 2345579 and 2698730) and Urografin inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle delisted 1 August 2026.				

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2026 (continued)

SPECIAL FOODS

301	AMINO ACID FORMULA (delisted) → Powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can 43.60	400 g	Alfamino
	Note – Pharmacode 2632187, delisted 1 August 2026.		
306	LOW ELECTROLYTE ORAL FEED 2 KCAL/ML (new listing) → Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton..... 13.72	4	Renilon 7.5 (apricot) Renilon 7.5 (caramel)
	Note – These are new Pharmacode listings, 2734265 (apricot) and 2734273 (caramel).		

Effective 1 July 2026

CARDIOVASCULAR SYSTEM

45	CANDESARTAN CILEXETIL		
	Tab 4 mg..... 2.92	98	Candesartan Mylan
		30	Candesartan Sandoz S29 AU
	Tab 8 mg..... 1.91	30	Apo-Candesartan
	Tab 16 mg..... 2.84	30	Apo-Candesartan
	Tab 32 mg..... 3.95	30	Apo-Candesartan

Index

Pharmaceuticals and brands

A

Alfamino	6
Amdipharm	4
AMIKACIN.....	4
AMINO ACID FORMULA	6
Apo-Candesartan	6
AZTREONAM.....	4
Aztreonam (Fresenius Kabi).....	4

C

CANDESARTAN CILEXETIL.....	6
Candesartan Mylan	6
Candesartan Sandoz S29 AU.....	6

D

DBL Promethazine Hydrochloride	5
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE	5

E

Eritrotex	4
ERYTHROMYCIN (AS LACTOBIONATE).....	4

G

Gastrografin	5
GRANISETRON	4
Granisetron-AFT	4

I

Ifomid - M.....	5
IFOSFAMIDE WITH MESNA.....	5

K

Ketalar	4
KETAMINE	4

L

Lenalidomide Viatris	5
LENALIDOMIDE (VIATRIS).....	5
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML	6

O

OESTRADIOL VALERATE.....	4
--------------------------	---

P

PARECOXIB	4
Parecoxib Juno	4
Progynova	4
PROMETHAZINE HYDROCHLORIDE.....	5
PROPRANOLOL	4
Propranolol LA Lupin.....	4

R

Renilon 7.5 (apricot)	6
Renilon 7.5 (caramel).....	6
RITUXIMAB (RIXIMYO)	5
Riximyo	5

T

TETRACYCLINE.....	4
Tetracycline AA.....	4

U

Urografin.....	5
----------------	---

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

